|
WO1994029351A2
(fr)
|
1993-06-16 |
1994-12-22 |
Celltech Limited |
Anticorps
|
|
WO1995001997A1
(fr)
|
1993-07-09 |
1995-01-19 |
Smithkline Beecham Corporation |
ANTICORPS RECOMBINANTS ET HUMANISES, DIRIGES CONTRE L'IL-1β ET DESTINES AU TRAITEMENT DE TROUBLES INFLAMMATOIRES INDUITS PAR IL-1 CHEZ L'HOMME
|
|
US5821332A
(en)
|
1993-11-03 |
1998-10-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Receptor on the surface of activated CD4+ T-cells: ACT-4
|
|
US5759546A
(en)
|
1994-02-04 |
1998-06-02 |
Weinberg; Andrew D. |
Treatment of CD4 T-cell mediated conditions
|
|
US6242566B1
(en)
|
1994-02-10 |
2001-06-05 |
Board Of Trustees Of The Leland Stanford Junior University |
Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
|
|
AU728657B2
(en)
|
1996-03-18 |
2001-01-18 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
WO1998023289A1
(fr)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
Modulation de la fixation de l'igg au fcrn
|
|
EP1997893A1
(fr)
|
1998-02-24 |
2008-12-03 |
Sisters of Providence in Oregon |
Compositions contenant un agent de liaison de récepteur OX-40 ou un acide nucléique l'encodant et procédés d'amélioration d'une réponse immunitaire antigène spécifique
|
|
US6312700B1
(en)
|
1998-02-24 |
2001-11-06 |
Andrew D. Weinberg |
Method for enhancing an antigen specific immune response with OX-40L
|
|
DK2112166T3
(en)
|
1998-12-23 |
2019-02-04 |
Pfizer |
Human monoclonal antibodies to CTLA-4
|
|
KR101077001B1
(ko)
|
1999-01-15 |
2011-10-26 |
제넨테크, 인크. |
효과기 기능이 변화된 폴리펩티드 변이체
|
|
US20030035790A1
(en)
|
1999-01-15 |
2003-02-20 |
Shu-Hsia Chen |
Combination therapy for the prevention or treatment of cancer, inflammatory disorders or infectious diseases in a subject
|
|
NZ517202A
(en)
|
1999-08-24 |
2004-05-28 |
Medarex Inc |
Human CTLA-4 antibodies and their uses
|
|
ES2637801T3
(es)
|
2000-04-11 |
2017-10-17 |
Genentech, Inc. |
Anticuerpos multivalentes y usos de los mismos
|
|
JP2004531457A
(ja)
|
2000-10-02 |
2004-10-14 |
ザ スクリプス リサーチ インスティテュート |
Ｔ細胞活性化を調節するための方法および組成物ならびにそれらの使用
|
|
PT1355919E
(pt)
|
2000-12-12 |
2011-03-02 |
Medimmune Llc |
Moléculas com semivida longa, composições que as contêm e suas utilizações
|
|
US7829084B2
(en)
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US20150329617A1
(en)
|
2001-03-14 |
2015-11-19 |
Dynal Biotech Asa |
Novel MHC molecule constructs, and methods of employing these constructs for diagnosis and therapy, and uses of MHC molecules
|
|
CA2467242A1
(fr)
|
2001-11-20 |
2003-05-30 |
Seattle Genetics, Inc. |
Traitement des troubles immunologiques au moyen des anticorps anti-cd30
|
|
TW200303759A
(en)
|
2001-11-27 |
2003-09-16 |
Schering Corp |
Methods for treating cancer
|
|
WO2003059245A2
(fr)
|
2001-12-18 |
2003-07-24 |
J & J Research Pty Ltd |
Methode de traitement de l'asthme
|
|
AUPS054702A0
(en)
|
2002-02-14 |
2002-03-07 |
Immunaid Pty Ltd |
Cancer therapy
|
|
PL377028A1
(pl)
|
2002-03-26 |
2006-01-23 |
Immunex Corporation |
Sposoby wykorzystania ligandu Flt-3 w procedurach immunizacyjnych
|
|
PE20040079A1
(es)
|
2002-04-03 |
2004-04-19 |
Novartis Ag |
Derivados de indolilmaleimida
|
|
US20030223989A1
(en)
|
2002-04-18 |
2003-12-04 |
Pluenneke John D. |
CD137 agonists to treat patients with IgE-mediated conditions
|
|
DE60317677T2
(de)
|
2002-06-13 |
2008-10-30 |
Crucell Holland B.V. |
Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung
|
|
US20040115216A1
(en)
|
2002-07-12 |
2004-06-17 |
The Johns Hopkins University |
Reagents and methods for engaging unique clonotypic lymphocyte receptors
|
|
US7291331B1
(en)
|
2002-09-11 |
2007-11-06 |
La Jolla Institute For Allergy And Immunology |
Methods of treating OX40 medicated recall immune responses
|
|
US20060148064A1
(en)
|
2002-10-25 |
2006-07-06 |
Srivastava Pramod K |
Apparatus and method for immunotherapy of a cancer through controlled cell lysis
|
|
DE10261223A1
(de)
|
2002-12-20 |
2004-07-08 |
MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH |
Steigerung der Immunantwort durch Substanzen, welche die Funktion von Natürlichen Killerzellen beeinflussen
|
|
JP2006512391A
(ja)
|
2002-12-30 |
2006-04-13 |
スリーエム イノベイティブ プロパティズ カンパニー |
組み合わせ免疫賦活薬
|
|
GB0303319D0
(en)
|
2003-02-13 |
2003-03-19 |
Novartis Ag |
Organic compounds
|
|
GB0303663D0
(en)
|
2003-02-18 |
2003-03-19 |
Lorantis Ltd |
Assays and medical treatments
|
|
US20040197312A1
(en)
|
2003-04-02 |
2004-10-07 |
Marina Moskalenko |
Cytokine-expressing cellular vaccine combinations
|
|
US7402431B2
(en)
|
2004-03-01 |
2008-07-22 |
Immunovative Therapies, Ltd. |
T-cell therapy formulation
|
|
US7435592B2
(en)
|
2003-05-13 |
2008-10-14 |
Immunovative Therapies, Ltd. |
Compositions for allogeneic cell therapy
|
|
JP2008501621A
(ja)
|
2003-05-31 |
2008-01-24 |
マイクロメット アクツィエン ゲゼルシャフト |
Ｂ細胞関連疾患を処置するための二重特異性抗ｃｄ３、抗ｃｄ１９抗体構築物を含む薬学的組成物
|
|
JP2007501866A
(ja)
|
2003-06-13 |
2007-02-01 |
マイクロバイア インコーポレイテッド |
胃腸疾患の治療のための方法および組成物
|
|
WO2005049085A1
(fr)
|
2003-11-18 |
2005-06-02 |
Valeocyte Therapies Llc |
Utilisation de complexes solubles pour faciliter l'activation cellulaire
|
|
EP1745037B1
(fr)
|
2004-01-19 |
2013-01-02 |
Novartis AG |
Dérivés d'indolylmaléimide utiles pour le traitment de rejets de greffe ou de maladies auto-immunes
|
|
US7592431B2
(en)
|
2004-02-26 |
2009-09-22 |
Immunovative Therapies, Ltd. |
Biodegradable T-cell Activation device
|
|
JP2007536254A
(ja)
|
2004-05-05 |
2007-12-13 |
メリマック ファーマシューティカルズ インコーポレーティッド |
生物活性を調節するための二重特異性結合剤
|
|
US7323235B2
(en)
|
2004-07-20 |
2008-01-29 |
Graham Group, Inc. |
Multi-strip promotional piece
|
|
US7563443B2
(en)
|
2004-09-17 |
2009-07-21 |
Domantis Limited |
Monovalent anti-CD40L antibody polypeptides and compositions thereof
|
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
|
MY146381A
(en)
|
2004-12-22 |
2012-08-15 |
Amgen Inc |
Compositions and methods relating relating to anti-igf-1 receptor antibodies
|
|
WO2006105021A2
(fr)
|
2005-03-25 |
2006-10-05 |
Tolerrx, Inc. |
Molecules de liaison gitr et leurs utilisations
|
|
PT2650020T
(pt)
|
2005-05-06 |
2016-12-12 |
Providence Health & Services - Oregon |
Proteína de fusão de imunoglobulina ox-40 trimérica e métodos do campo de utilização
|
|
GB0512225D0
(en)
|
2005-06-16 |
2005-07-27 |
Univ Sheffield |
Immunoglobulin molecules
|
|
JP2006345852A
(ja)
|
2005-06-16 |
2006-12-28 |
Virxsys Corp |
抗体複合体
|
|
WO2007016340A2
(fr)
|
2005-07-29 |
2007-02-08 |
Providence Health System |
Produits de ribosome défectueux dans les blebs (flux salivaires inconscients) et procédés d’utilisation pour stimuler une réponse immunitaire
|
|
US8137670B2
(en)
|
2005-09-29 |
2012-03-20 |
Medimmune, Llc |
Method of identifying membrane IgE specific antibodies and use thereof for targeting IgE producing precursor cells
|
|
TWI461436B
(zh)
|
2005-11-25 |
2014-11-21 |
Kyowa Hakko Kirin Co Ltd |
人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
|
|
AR057253A1
(es)
|
2005-12-16 |
2007-11-21 |
Genentech Inc |
Anticuerpos anti-ox40l y metodos que los utilizan
|
|
US20080286286A1
(en)
|
2006-01-13 |
2008-11-20 |
Board Of Regents, The University Of Texas System |
Methods to Treat Disease States by Influencing the Signaling of Ox-40-Receptors and High Throughput Screening Methods for Identifying Substances Therefor
|
|
US20110008368A1
(en)
|
2006-01-13 |
2011-01-13 |
Board Of Regents, The University Of Texas System |
Methods of modulating the ox40 receptor to treat cancer
|
|
US20110212086A1
(en)
|
2006-01-19 |
2011-09-01 |
Genzyme Corporation |
GITR Antibodies For The Treatment of Cancer
|
|
JP2009530391A
(ja)
|
2006-03-22 |
2009-08-27 |
インペリアル・イノベ−ションズ・リミテッド |
免疫系の因子の調節に関連する組成物および方法
|
|
WO2007130555A2
(fr)
|
2006-05-02 |
2007-11-15 |
Providence Health System |
Augmentation de la réaction immunitaire au vaccin contre le cancer
|
|
EP2418223A3
(fr)
|
2006-06-12 |
2013-01-16 |
Emergent Product Development Seattle, LLC |
Protéines de liaison polyvalente à chaîne unique avec une fonction effectrice
|
|
US10106619B2
(en)
|
2006-10-04 |
2018-10-23 |
La Jolla Institute For Allergy And Immunology |
Virus vaccination and treatment methods with OX40 agonist compositions
|
|
EP1914242A1
(fr)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Nouveau anticorps Anti-CD38 pour le traitement du cancer
|
|
GB0620894D0
(en)
|
2006-10-20 |
2006-11-29 |
Univ Southampton |
Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
|
|
CA2679399A1
(fr)
|
2007-02-27 |
2008-09-04 |
Genetech, Inc. |
Anticorps antagoniste d'ox40, et leur utilisation dans le traitement de maladies inflammatoires et auto-immunes
|
|
JP2008278814A
(ja)
|
2007-05-11 |
2008-11-20 |
Igaku Seibutsugaku Kenkyusho:Kk |
アゴニスティック抗ヒトｇｉｔｒ抗体による免疫制御の解除とその応用
|
|
EP2185590A2
(fr)
|
2007-09-07 |
2010-05-19 |
Symphogen A/S |
Méthodes de production recombinante d'anticorps anti-rsv
|
|
EP2192922A4
(fr)
|
2007-09-17 |
2010-09-29 |
Univ California |
Anticorps monoclonaux humains internalisants ciblant des cellules du cancer de la prostate<i>in situ</i>
|
|
HUE032735T2
(en)
|
2007-12-14 |
2017-10-30 |
Bristol Myers Squibb Co |
Binding molecules for the human OX40 receptor
|
|
EP2240204A1
(fr)
|
2008-02-04 |
2010-10-20 |
Medarex, Inc. |
Anticorps anti-clta-4 avec blocage réduit de la liaison de ctla-4 à b7 et leurs utilisations
|
|
WO2009141239A1
(fr)
|
2008-05-20 |
2009-11-26 |
F. Hoffmann-La Roche Ag |
Formulation pharmaceutique comprenant un anticorps contre ox40l, utilisations de celle-ci
|
|
PL2315756T3
(pl)
|
2008-07-08 |
2015-02-27 |
Incyte Holdings Corp |
1,2,5-oksadiazole jako inhibitory 2,3-dioksygenazy indoloaminy
|
|
WO2010037395A2
(fr)
|
2008-10-01 |
2010-04-08 |
Dako Denmark A/S |
Multimères de mhc dans des vaccins et la surveillance immunitaire contre le cancer
|
|
DK2356270T3
(da)
|
2008-11-07 |
2016-12-12 |
Fabrus Llc |
Kombinatoriske antistofbiblioteker og anvendelser deraf
|
|
CN102272158B
(zh)
|
2008-11-12 |
2014-05-07 |
乔治·K·刘易斯 |
源自记忆b细胞的人单克隆抗体的快速表达克隆
|
|
EP2398498B1
(fr)
|
2009-02-17 |
2018-09-05 |
UCB Biopharma SPRL |
Molécules d'anticorps ayant une spécificité pour ox40 humain
|
|
WO2010110346A1
(fr)
|
2009-03-24 |
2010-09-30 |
独立行政法人理化学研究所 |
Marqueurs de cellules souches leucémiques
|
|
RU2595409C2
(ru)
*
|
2009-09-03 |
2016-08-27 |
Мерк Шарп И Доум Корп., |
Анти-gitr-антитела
|
|
CN102753195A
(zh)
|
2009-12-07 |
2012-10-24 |
小利兰·斯坦福大学托管委员会 |
用于增强抗肿瘤抗体疗法的方法
|
|
GB201000467D0
(en)
|
2010-01-12 |
2010-02-24 |
Ucb Pharma Sa |
Antibodies
|
|
CA3253628A1
(en)
|
2010-03-05 |
2025-11-29 |
The Johns Hopkins University |
Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
|
|
GB201006096D0
(en)
|
2010-04-13 |
2010-05-26 |
Alligator Bioscience Ab |
Novel compositions and uses thereof
|
|
US20110256184A1
(en)
|
2010-04-14 |
2011-10-20 |
Battelle Memorial Institute |
Non-ordered Mesoporous Silica Structure for Biomolecule Loading and Release
|
|
EP2399604A1
(fr)
|
2010-06-25 |
2011-12-28 |
F. Hoffmann-La Roche AG |
Nouvelle formulation d'anticorps
|
|
WO2012012518A2
(fr)
|
2010-07-20 |
2012-01-26 |
University Of Miami |
Inhibition des voies de dégradation des arnm non-sens
|
|
PL2609118T3
(pl)
|
2010-08-23 |
2017-07-31 |
Board Of Regents, The University Of Texas System |
Przeciwciała anty-OX40 i sposoby ich stosowania
|
|
WO2012064760A2
(fr)
|
2010-11-08 |
2012-05-18 |
Biovest International, Inc. |
Matériels et méthodes pour l'orientation d'une réponse immunitaire vers un épitope
|
|
JP5828909B2
(ja)
|
2011-01-10 |
2015-12-09 |
シーティー アトランティック リミテッド |
腫瘍関連抗原結合抗体を含む併用療法
|
|
BR112013024574B1
(pt)
|
2011-03-29 |
2022-08-09 |
Roche Glycart Ag |
Anticorpo e uso do anticorpo
|
|
KR20140029446A
(ko)
|
2011-04-15 |
2014-03-10 |
컴퓨젠 엘티디. |
면역 관련 장애 및 암의 치료를 위한 폴리펩티드 및 폴리뉴클레오티드, 및 이들의 용도
|
|
US20140186363A1
(en)
|
2011-06-03 |
2014-07-03 |
University Of Zurich |
Magea3 binding antibodies
|
|
AU2012273182A1
(en)
|
2011-06-21 |
2014-01-16 |
The Johns Hopkins University |
Focused radiation for augmenting immune-based therapies against neoplasms
|
|
EP2731677B1
(fr)
*
|
2011-07-11 |
2018-04-18 |
Glenmark Pharmaceuticals S.A. |
Anticorps qui se lient à l'ox40 et leurs utilisations
|
|
EP3939613A1
(fr)
|
2011-08-11 |
2022-01-19 |
ONO Pharmaceutical Co., Ltd. |
Agent thérapeutique destiné à des maladies auto-immunes comprenant un agoniste de pd-1
|
|
KR101685262B1
(ko)
|
2011-08-23 |
2016-12-21 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
항-ｏｘ４０ 항체 및 이의 사용 방법
|
|
US8920075B2
(en)
|
2011-09-01 |
2014-12-30 |
Halo Maritime Defense Systems, Inc. |
Marine barrier and gate
|
|
WO2013039954A1
(fr)
*
|
2011-09-14 |
2013-03-21 |
Sanofi |
Anticorps anti-gitr
|
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
|
US20130071403A1
(en)
|
2011-09-20 |
2013-03-21 |
Vical Incorporated |
Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
|
|
WO2013049307A2
(fr)
|
2011-09-30 |
2013-04-04 |
University Of Miami |
Développement d'une mémoire immunitaire améliorée par une inhibition de mtor des lymphocytes t ciblée par un aptamère
|
|
SI2776466T1
(sl)
|
2011-11-11 |
2017-12-29 |
Ucb Biopharma Sprl |
Protitelesa, ki se vežejo na albumin in njihovi vezavni fragmenti
|
|
UA112203C2
(uk)
|
2011-11-11 |
2016-08-10 |
Юсб Фарма С.А. |
Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
|
|
DK2785683T3
(da)
|
2011-11-30 |
2020-04-14 |
Ludwig Inst For Cancer Res Ltd |
Inkt-cellemodulatorer og fremgangsmåder til anvendelse heraf
|
|
GB201120860D0
(en)
|
2011-12-05 |
2012-01-18 |
Cambridge Entpr Ltd |
Cancer immunotherapy
|
|
EP2794658B1
(fr)
|
2011-12-19 |
2017-03-15 |
Synimmune GmbH |
Molécule d'anticorps bispécifique
|
|
WO2013112942A1
(fr)
|
2012-01-25 |
2013-08-01 |
Dna Trix, Inc. |
Biomarqueurs et polythérapies utilisant un virus oncolytique et l'immunomodulation
|
|
US9617336B2
(en)
|
2012-02-01 |
2017-04-11 |
Compugen Ltd |
C10RF32 antibodies, and uses thereof for treatment of cancer
|
|
CA2863818A1
(fr)
|
2012-02-06 |
2013-08-15 |
Brendan CURTI |
Traitement du cancer et procedes de surveillance utilisant des agonistes de ox40
|
|
LT2814844T
(lt)
|
2012-02-15 |
2017-10-25 |
Novo Nordisk A/S |
Antikūnai, kurie jungiasi ir blokuoja ekspresuotą ant mieloidinių ląstelių inicijuojantį receptorių 1 (trem-1)
|
|
AU2013222288A1
(en)
|
2012-02-22 |
2014-08-14 |
The Trustees Of The University Of Pennsylvania |
Use of ICOS-based CARs to enhance antitumor activity and CAR persistence
|
|
EP2817619B1
(fr)
|
2012-02-23 |
2018-07-25 |
Sloan Kettering Institute For Cancer Research |
Prédiction de la sensibilité à un traitement par des produits thérapeutiques d'immunomodulation et procédé de surveillance des effets ascopaux au cours d'un tel traitement
|
|
EP2819693A4
(fr)
|
2012-03-02 |
2015-10-28 |
Providence Health & Services Oregon |
Bithérapie anticancéreuse basée sur l'agoniste ox40/il-2
|
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
|
US8993614B2
(en)
|
2012-03-15 |
2015-03-31 |
F. Hoffmann-La Roche Ag |
Substituted pyrrolidine-2-carboxamides
|
|
SG10201704992SA
(en)
|
2012-06-21 |
2017-07-28 |
Compugen Ltd |
Lsr antibodies, and uses thereof for treatment of cancer
|
|
ES2723885T3
(es)
*
|
2012-07-19 |
2019-09-03 |
Daiichi Sankyo Co Ltd |
Anticuerpos anti-Siglec-15
|
|
US20150190505A1
(en)
|
2012-07-30 |
2015-07-09 |
Alex Wah Hin Yeung |
Live and in-vivo tumor specific cancer vaccine system developed by co-administration of either at least two or all three of the following components such as tumor cells, an oncolytic virus vector with transgenic expression of gm-csf and an immune checkpoint modulator
|
|
WO2014022592A1
(fr)
|
2012-08-02 |
2014-02-06 |
Jn Biosciences Llc |
Anticorps ou protéines de fusion multimérisés par l'intermédiaire de la mutation d'une cystéine et une pièce de queue μ
|
|
WO2015116178A1
(fr)
|
2014-01-31 |
2015-08-06 |
Thomas Jefferson University |
Protéines de fusion pour la modulation des lymphocytes t régulateurs et effecteurs
|
|
WO2014121099A1
(fr)
|
2013-01-31 |
2014-08-07 |
Thomas Jefferson University |
Protéine de fusion agoniste des cd40 ox40 et ses utilisations
|
|
US9834610B2
(en)
|
2013-01-31 |
2017-12-05 |
Thomas Jefferson University |
Fusion proteins for modulating regulatory and effector T cells
|
|
US11083743B2
(en)
|
2013-02-21 |
2021-08-10 |
Michele Maio |
DNA hypomethylating agents for cancer therapy
|
|
NZ712903A
(en)
|
2013-03-18 |
2018-07-27 |
Biocerox Prod Bv |
Humanized anti-cd134 (ox40) antibodies and uses thereof
|
|
WO2014165771A2
(fr)
|
2013-04-05 |
2014-10-09 |
Genentech, Inc. |
Anticorps anti-il-4 et anticorps bispécifiques et leurs utilisations
|
|
CA2919513A1
(fr)
|
2013-07-15 |
2015-01-22 |
Matthew J. Goldstein |
Utilisations medicales d'agonistes de cd38
|
|
AU2014290069B2
(en)
|
2013-07-16 |
2019-01-03 |
Genentech, Inc. |
Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
|
|
DK3406633T3
(da)
*
|
2013-07-25 |
2022-03-28 |
Cytomx Therapeutics Inc |
Multispecifikke antistoffer, multispecifikke aktiverbare antistoffer og fremgangsmåder til anvendelse heraf
|
|
AR097306A1
(es)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
|
TW201605896A
(zh)
*
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
|
WO2015035112A1
(fr)
|
2013-09-05 |
2015-03-12 |
The Johns Hopkins University |
Thérapie anticancéreuse par l'intermédiaire d'une combinaison de modulation épigénétique et modulation immunitaire
|
|
EP3066133A1
(fr)
|
2013-11-04 |
2016-09-14 |
Glenmark Pharmaceuticals S.A. |
Production de cellules t reciblant des immunoglobulines héréro-dimériques
|
|
US20150273033A1
(en)
|
2013-11-05 |
2015-10-01 |
Cognate Bioservices, Inc. |
Combinations of checkpoint inhibitors and therapeutics to treat cancer
|
|
KR20160137946A
(ko)
|
2013-11-22 |
2016-12-02 |
디엔에이트릭스, 인코포레이티드 |
면역 세포 자극성 수용체 작용제(들)를 발현하는 아데노바이러스
|
|
CA2934028A1
(fr)
|
2013-12-17 |
2015-06-25 |
Genentech, Inc. |
Polytherapie comprenant des agonistes se liant a ox40 et des antagonistes se liant a l'axe pd-1
|
|
JP7060324B2
(ja)
|
2013-12-20 |
2022-04-26 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
ネオ抗原ワクチンによる併用療法
|
|
RS63295B1
(sr)
|
2013-12-24 |
2022-06-30 |
Janssen Pharmaceutica Nv |
Anti-vista antitela i fragmenti
|
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
|
US10307472B2
(en)
|
2014-03-12 |
2019-06-04 |
Curevac Ag |
Combination of vaccination and OX40 agonists
|
|
ES3040431T3
(en)
|
2014-03-12 |
2025-10-31 |
Yeda Res & Dev |
Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
|
|
EP3122779B1
(fr)
|
2014-03-24 |
2019-05-22 |
Cancer Research Technology Limited |
Anticorps modifiés contenant des domaines d'igg2 modifiés conférant des propriétés agonistes ou antagonistes, et utilisation de ces derniers
|
|
HRP20192285T1
(hr)
|
2014-03-31 |
2020-03-06 |
F. Hoffmann - La Roche Ag |
Anti-ox40 protutijela i postupci uporabe
|
|
RU2016142476A
(ru)
|
2014-03-31 |
2018-05-07 |
Дженентек, Инк. |
Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
|
|
RU2689162C2
(ru)
|
2014-04-03 |
2019-05-24 |
Огаста Юниверсити Рисерч Инститьют, Инк. |
Способы повышения эффективности противоопухолевого иммунного ответа
|
|
US20170165230A1
(en)
|
2014-04-09 |
2017-06-15 |
Christopher Rudd |
Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
|
|
US20150307620A1
(en)
|
2014-04-16 |
2015-10-29 |
University Of Connecticut |
Linked immunotherapeutic agonists that costimulate multiple pathways
|
|
EP2939690A1
(fr)
|
2014-04-29 |
2015-11-04 |
Medizinische Hochschule Hannover |
Vaccins
|
|
CA2947157A1
(fr)
|
2014-05-13 |
2015-11-19 |
Chugai Seiyaku Kabushiki Kaisha |
Molecule de liaison a un antigene redirige vers un lymphocyte t pour cellules presentant une fonction d'immunosuppression
|
|
AU2015266958A1
(en)
*
|
2014-05-28 |
2016-12-08 |
Agenus Inc. |
Anti-GITR antibodies and methods of use thereof
|
|
JP6449338B2
(ja)
|
2014-06-06 |
2019-01-09 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
グルココルチコイド誘導腫瘍壊死因子受容体（ｇｉｔｒ）に対する抗体およびその使用
|
|
US10449227B2
(en)
|
2014-06-27 |
2019-10-22 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Conjugates for immunotherapy
|
|
WO2015197874A2
(fr)
|
2014-06-27 |
2015-12-30 |
Apogenix Gmbh |
Combinaison d'inhibition du cd95/cd95l et d'immunothérapie du cancer
|
|
CN112546230A
(zh)
|
2014-07-09 |
2021-03-26 |
博笛生物科技有限公司 |
用于治疗癌症的联合治疗组合物和联合治疗方法
|
|
JP2017522322A
(ja)
|
2014-07-18 |
2017-08-10 |
アドバクシス， インコーポレイテッド |
抗腫瘍応答を引き出すためのリステリアベースの免疫原性組成物
|
|
US20170216403A1
(en)
|
2014-08-12 |
2017-08-03 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
|
|
MY198017A
(en)
|
2014-08-19 |
2023-07-26 |
Merck Sharp & Dohme |
Anti-tigit antibodies
|
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
|
EP3191126B1
(fr)
|
2014-09-13 |
2020-05-13 |
Novartis AG |
Thérapies combinées d'inhibiteurs d'alk
|
|
RU2017115315A
(ru)
|
2014-10-03 |
2018-11-08 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
|
|
EP3662903A3
(fr)
|
2014-10-03 |
2020-10-14 |
Novartis AG |
Polythérapies
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
TW201619200A
(zh)
|
2014-10-10 |
2016-06-01 |
麥迪紐有限責任公司 |
人類化抗－ｏｘ４０抗體及其用途
|
|
US20160101128A1
(en)
|
2014-10-10 |
2016-04-14 |
Idera Pharmaceuticals, Inc. |
Treatment of cancer using tlr9 agonist with checkpoint inhibitors
|
|
WO2016059602A2
(fr)
|
2014-10-16 |
2016-04-21 |
Glaxo Group Limited |
Méthodes de traitement du cancer et compositions associées
|
|
CN115920007A
(zh)
|
2014-10-24 |
2023-04-07 |
阿斯利康(瑞典)有限公司 |
组合
|
|
NZ732211A
(en)
|
2014-10-24 |
2020-04-24 |
Calidi Biotherapeutics Inc |
Combination immunotherapy approach for treatment of cancer
|
|
EP3212228B1
(fr)
|
2014-10-27 |
2025-12-03 |
Ruprecht-Karls-Universität Heidelberg |
Maraviroc seul ou en thérapie combinée pour le traitement du cancer
|
|
JP7305300B2
(ja)
|
2014-11-05 |
2023-07-10 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
併用免疫療法
|
|
KR20170072343A
(ko)
|
2014-11-06 |
2017-06-26 |
제넨테크, 인크. |
Ox40 결합 효능제 및 tigit 억제제를 포함하는 병용 요법
|
|
JP2018500384A
(ja)
|
2014-11-11 |
2018-01-11 |
メディミューン リミテッド |
腫瘍形成を治療するための治療の組合せ
|
|
LT3221346T
(lt)
|
2014-11-21 |
2020-11-10 |
Bristol-Myers Squibb Company |
Antikūnai, apimantys modifikuotas sunkiosios grandinės pastoviąsias sritis
|
|
EP3226900A4
(fr)
|
2014-12-05 |
2018-09-19 |
Immunext, Inc. |
Identification de vsig8 en tant que récepteur putatif de vista et son utilisation pour produire des modulateurs de vista/vsig8
|
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗ｐｄ－１抗體類和使用彼等之方法
|
|
IL320860A
(en)
|
2014-12-19 |
2025-07-01 |
Dana Farber Cancer Inst Inc |
Chimeric antigen receptors and methods of using them
|
|
EP3233918A1
(fr)
|
2014-12-19 |
2017-10-25 |
Novartis AG |
Polythérapies
|
|
RS63384B1
(sr)
|
2015-01-08 |
2022-08-31 |
BioNTech SE |
Agonistička sredstva za vezivanje tnf receptora
|
|
GB201500319D0
(en)
|
2015-01-09 |
2015-02-25 |
Agency Science Tech & Res |
Anti-PD-L1 antibodies
|
|
WO2016145030A1
(fr)
|
2015-03-11 |
2016-09-15 |
Providence Health & Services-Oregon |
Compositions et méthodes pour améliorer l'efficacité de traitement du cancer
|
|
EP4537906A3
(fr)
|
2015-03-25 |
2025-08-20 |
The Regents of the University of Michigan |
Compositions et procédés pour l'administration d'agents biomacromolécules
|
|
WO2016168361A1
(fr)
|
2015-04-14 |
2016-10-20 |
Polynoma, Llc |
Vaccins polyvalents et thérapie de combinaison pour le traitement de mélanome
|
|
SG11201708223QA
(en)
|
2015-04-17 |
2017-11-29 |
Bristol Myers Squibb Co |
Compositions comprising a combination of an anti-pd-1 antibody and another antibody
|
|
PH12017502013B1
(en)
|
2015-05-07 |
2022-07-22 |
Agenus Inc |
Anti-ox40 antibodies and methods of use thereof
|
|
AU2016263198C1
(en)
|
2015-05-15 |
2023-10-05 |
The General Hospital Corporation |
Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
|
|
US20160347848A1
(en)
|
2015-05-28 |
2016-12-01 |
Medimmune Limited |
Therapeutic combinations and methods for treating neoplasia
|
|
UY36687A
(es)
|
2015-05-29 |
2016-11-30 |
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware |
Anticuerpos contra ox40 y sus usos
|
|
KR20180068990A
(ko)
|
2015-10-01 |
2018-06-22 |
포텐자 테라퓨틱스, 인코포레이티드 |
항-tigit 항체-결합 단백질 및 이의 사용 방법
|
|
EP3383914A4
(fr)
|
2015-12-02 |
2019-10-30 |
Agenus Inc. |
Anticorps anti-ox40 et leurs procédés d'utilisation
|
|
WO2017096276A1
(fr)
|
2015-12-02 |
2017-06-08 |
Agenus Inc. |
Anticorps anti-gitr et procédés d'utilisation associés
|
|
AU2016364895A1
(en)
|
2015-12-02 |
2018-06-07 |
Agenus Inc. |
Anti-GITR antibodies and methods of use thereof
|
|
SG10201912984WA
(en)
|
2015-12-02 |
2020-03-30 |
Agenus Inc |
Antibodies and methods of use thereof
|
|
CA3006963A1
(fr)
|
2015-12-03 |
2017-06-08 |
Ludwig Institute For Cancer Research Ltd. |
Anticorps anti-ox40 et leurs procedes d'utilisation
|
|
LT3429618T
(lt)
|
2016-03-16 |
2024-05-10 |
Amal Therapeutics Sa |
Imuninės sistemos patikros taško moduliatoriaus ir komplekso, apimančio į ląsteles prasiskverbiantį peptidą, krovinį ir tlr peptido agonistą, derinys, skirtas naudoti medicinoje
|
|
US11596699B2
(en)
|
2016-04-29 |
2023-03-07 |
CureVac SE |
RNA encoding an antibody
|
|
EP3538152A4
(fr)
|
2016-11-09 |
2020-09-30 |
Agenus Inc. |
Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
|